Literature DB >> 33438142

Novel compound heterozygous variants in the GFPT1 gene leading to rare limb-girdle congenital myasthenic syndrome with rimmed vacuoles.

Yanyan Ma1, Ting Xiong1, Guohua Lei2, Jiaqi Ding3, Rui Yang1, Zunbo Li4, Jun Guo5, Dingguo Shen6.   

Abstract

BACKGROUND: Congenital myasthenic syndrome (CMS) is a heterogeneous group of rare disorders with impaired neuromuscular transmission caused by genetic defects, which is characterized by fatigable muscle weakness. CASE
PRESENTATION: Herein, we report a case of limb-girdle CMS (LG-CMS) in a 15-year-old Chinese girl with limb weakness and mild ptosis. The patient presented with well-defined clinical manifestations, muscle imaging, and electrophysiological features associated with CMS. On muscle biopsy, in addition to tubular aggregates identified, an extremely unusual pathological change of rimmed vacuoles in muscle fibers was observed. Whole-exome sequencing disclosed two novel heterozygous variants (c.14 T>A and c.581 T>C) in the human glutamine-fructose-6-phosphate transaminase 1 (GFPT1) gene, leading to the substitutions of phenylalanine to tyrosine (p.F5Y) and serine (p.F194S), respectively. Both variants were predicted to be likely pathogenic by SIFT, Polyphen-2, and Mutation Taster. Treatments with pyridostigmine bromide and albuterol produced a dramatic improvement.
CONCLUSIONS: Collectively, molecular genetic analysis and muscle biopsy play crucial roles in the diagnosis of GFPT1-related LG-CMS with rimmed vacuoles (a rare phenotype of CMS) and have important implications for treatment decision.
© 2020. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Congenital myasthenic syndrome; GFPT1; Limb-girdle myasthenia; Neuromuscular junction; Rimmed vacuoles

Year:  2021        PMID: 33438142     DOI: 10.1007/s10072-020-05021-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

1.  Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy.

Authors:  Stéphanie Bauché; Geoffroy Vellieux; Damien Sternberg; Marie-Joséphine Fontenille; Elodie De Bruyckere; Claire-Sophie Davoine; Guy Brochier; Julien Messéant; Lucie Wolf; Michel Fardeau; Emmanuelle Lacène; Norma Romero; Jeanine Koenig; Emmanuel Fournier; Daniel Hantaï; Nathalie Streichenberger; Veronique Manel; Arnaud Lacour; Aleksandra Nadaj-Pakleza; Sylvie Sukno; Françoise Bouhour; Pascal Laforêt; Bertrand Fontaine; Laure Strochlic; Bruno Eymard; Frédéric Chevessier; Tanya Stojkovic; Sophie Nicole
Journal:  J Neurol       Date:  2017-07-15       Impact factor: 4.849

Review 2.  Congenital myasthenic syndromes.

Authors:  Bruno Eymard; Daniel Hantaï; Brigitte Estournet
Journal:  Handb Clin Neurol       Date:  2013

Review 3.  Clinical and genetic basis of congenital myasthenic syndromes.

Authors:  Paulo Victor Sgobbi de Souza; Gabriel Novaes de Rezende Batistella; Valéria Cavalcante Lino; Wladimir Bocca Vieira de Rezende Pinto; Marcelo Annes; Acary Souza Bulle Oliveira
Journal:  Arq Neuropsiquiatr       Date:  2016-09       Impact factor: 1.420

Review 4.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

5.  GFPT1-myasthenia: clinical, structural, and electrophysiologic heterogeneity.

Authors:  Duygu Selcen; Xin-Ming Shen; Margherita Milone; Joan Brengman; Kinji Ohno; Feza Deymeer; Richard Finkel; Julie Rowin; Andrew G Engel
Journal:  Neurology       Date:  2013-06-21       Impact factor: 9.910

Review 6.  Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

7.  Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome.

Authors:  Roger G Whittaker; David N Herrmann; Boglarka Bansagi; Bashar Awwad Shiekh Hasan; Robert Muni Lofra; Eric L Logigian; Janet E Sowden; Jorge L Almodovar; J Troy Littleton; Stephan Zuchner; Rita Horvath; Hanns Lochmüller
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

8.  How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia.

Authors:  Jeremy Ross Parr; Morag Jane Andrew; Maria Finnis; David Beeson; Angela Vincent; Sandeep Jayawant
Journal:  Arch Dis Child       Date:  2014-02-05       Impact factor: 3.791

Review 9.  Congenital myasthenic syndromes and the neuromuscular junction.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; David Beeson
Journal:  Curr Opin Neurol       Date:  2014-10       Impact factor: 5.710

10.  Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.

Authors:  Sarah Finlayson; Jennifer Spillane; Dimitri M Kullmann; Robin Howard; Richard Webster; Jacqueline Palace; David Beeson
Journal:  Muscle Nerve       Date:  2012-12-28       Impact factor: 3.217

View more
  3 in total

1.  Clinicopathological-genetic features of congenital myasthenic syndrome from a Chinese neuromuscular centre.

Authors:  Kun Huang; Hui-Qian Duan; Qiu-Xiang Li; Yue-Bei Luo; Fang-Fang Bi; Huan Yang
Journal:  J Cell Mol Med       Date:  2022-06-06       Impact factor: 5.295

2.  Diverse myopathological features in the congenital myasthenia syndrome with GFPT1 mutation.

Authors:  Kaiyan Jiang; Yilei Zheng; Jing Lin; Xiaorong Wu; Yanyan Yu; Min Zhu; Xin Fang; Meihong Zhou; Xiaobing Li; Daojun Hong
Journal:  Brain Behav       Date:  2022-01-03       Impact factor: 3.405

3.  Abnormal decrement on high-frequency repetitive nerve stimulation in congenital myasthenic syndrome with GFPT1 mutations and review of literature.

Authors:  Ran An; Huijiao Chen; Song Lei; Yi Li; Yanming Xu; Chengqi He
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.